DelveInsight’s, “Myocardial Infarction Pipeline Insight, 2025” report provides comprehensive insights about 30+ companies and 40+ pipeline drugs in Myocardial Infarction pipeline landscape. It covers the Myocardial Infarction pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myocardial Infarction pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Myocardial Infarction Treatment Landscape @ Myocardial Infarction Pipeline Outlook
Key Takeaways from the Myocardial Infarction Pipeline Report
- On 19 August 2025, Boehringer Ingelheim conducted a study is open to adults aged 18 and over who have just had a heart attack. The purpose of this study is to find out whether a medicine called BI 765845 helps people who have had a heart attack. The investigators also want to test how well different doses of BI 765845 work and how they are tolerated by people who have had a heart attack.
- DelveInsight’s Myocardial Infarction pipeline report depicts a robust space with 30+ active players working to develop 40+ pipeline therapies for Myocardial Infarction treatment.
- The leading Myocardial Infarction Companies such as Novo Nordisk, CeleCor Therapeutics, Bayer, Shanghai Zhongshan Hospital, Takeda Pharmaceuticals, Nexel, Moleac Pte Ltd., LIB Therapeutics, Windtree Therapeutics, Faraday Pharmaceuticals, CSL Behring, Cardior Pharmaceuticals, AstraZeneca, R-Pharma, Shilpa Biologicals and others.
- Promising Myocardial Infarction Pipeline Therapies such as Ilomedin, MiSaver®, BI 765845, Empagliflozin, Tenecteplase, Clopidogrel, Enoxaparin, Eplerenone, and others.
Stay informed about the cutting-edge advancements in Myocardial Infarction treatments. Download for updates and be a part of the revolution in Cardiovascular Diseases Care @ Myocardial Infarction Clinical Trials Assessment
Myocardial Infarction Emerging Drugs Profile
- FDY 5301: Faraday Pharmaceuticals
FDY-5301 is an elemental reducing agent containing sodium iodide for which Faraday has obtained method of use patent protection in major markets worldwide. Faraday has selected FDY-5301 for investigation in the belief that its properties are uniquely well-suited to mitigate ischemia-reperfusion injury (IRI). In preclinical IRI models, FDY-5301 reduced tissue damage, infarct size, and inflammation. FDY-5301 functions as a catalytic neutralizer of hydrogen peroxide, a prominent reactive oxygen species implicated in the IRI cascade leading to cardiomyocyte death, and also acts as an immunomodulating agent. Currently, the drug is in Phase III stage of its clinical trial for the treatment AMI.
- Glenzocimab: Acticor Biotech
Glenzocimab is a humanized monoclonal antibody fragment designed to target the human platelet glycoprotein VI (GPVI), which plays a crucial role in thrombus formation and stability. Its mechanism of action involves inhibiting platelet activation and aggregation, particularly in the context of ischemic stroke and myocardial infarction. Currently, it is in Phase II stage of its clinical trial for the treatment of myocardial infarction.
- BI765845: Boehringer Ingelheim
BI765845 is an experimental drug developed by Boehringer Ingelheim, classified as an anti-ischemic agent. It aims to address ischemic conditions by improving oxygen supply and reducing oxygen demand in affected tissues. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Myocardial infarction.
The Myocardial Infarction Pipeline Report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Myocardial Infarction with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myocardial Infarction Treatment.
- Myocardial Infarction Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Myocardial Infarction Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myocardial Infarction market.
Learn more about Myocardial Infarction Drugs opportunities in our groundbreaking Myocardial Infarction research and development projects @ Myocardial Infarction Unmet Needs
Myocardial Infarction Companies
Novo Nordisk, CeleCor Therapeutics, Bayer, Shanghai Zhongshan Hospital, Takeda Pharmaceuticals, Nexel, Moleac Pte Ltd., LIB Therapeutics, Windtree Therapeutics, Faraday Pharmaceuticals, CSL Behring, Cardior Pharmaceuticals, AstraZeneca, R-Pharma, Shilpa Biologicals and others.
Myocardial Infarction pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Myocardial Infarction Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
Stay informed about how we’re transforming the future of Cardiovascular Diseases @ Myocardial Infarction Market Drivers and Barriers, and Future Perspectives
Scope of the Myocardial Infarction Pipeline Report
- Coverage- Global
- Myocardial Infarction Companies- Novo Nordisk, CeleCor Therapeutics, Bayer, Shanghai Zhongshan Hospital, Takeda Pharmaceuticals, Nexel, Moleac Pte Ltd., LIB Therapeutics, Windtree Therapeutics, Faraday Pharmaceuticals, CSL Behring, Cardior Pharmaceuticals, AstraZeneca, R-Pharma, Shilpa Biologicals and others.
- Myocardial Infarction Pipeline Therapies- Ilomedin, MiSaver®, BI 765845, Empagliflozin, Tenecteplase, Clopidogrel, Enoxaparin, Eplerenone, and others.
- Myocardial Infarction Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Myocardial Infarction Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Myocardial Infarction Pipeline on our website @ Myocardial Infarction Emerging Drugs and Companies
Table of Contents
- Introduction
- Executive Summary
- Myocardial Infarction: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Myocardial Infarction – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- FDY 5301: Faraday Pharmaceuticals
- Mid Stage Products (Phase II)
- Glenzocimab: Acticor Biotech
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug Name: Company Name
- Mid Stage Products (Phase II)
- Preclinical Stage Products
- Drug Name: Company Name
- Inactive Products
- Myocardial Infarction – Collaborations Assessment- Licensing / Partnering / Funding
- Myocardial Infarction – Unmet Needs
- Myocardial Infarction – Market Drivers and Barriers
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/